Maria Elvira Buys Shares of Biogen Inc. (BIIB)

Maria Elvira, a House member, recently bought shares of Biogen Inc.

Written by Opentrades · Published Jun 12, 2026, 9:21 PM EDT · Updated Jun 13, 2026, 2:10 AM EDT

Key Points

Maria Elvira purchased Biogen Inc. shares valued between $1,001 and $15,000, according to a report filed on June 9, 2026.
Biogen's stock trades around $199.96 with a market cap of $29.5 billion and a P/E ratio of 21.5.
Analysts like Needham and RBC Capital have set price targets as high as $255, with a consensus recommendation to buy.

Congressional trading track record

Maria Elvira vs. the S&P 500

YTD return +15.5% hypothetical

All-time return -4.3% S&P 500 +57.2%

vs. S&P 500 -61.5% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

Maria Elvira, a member of the House, purchased shares of Biogen Inc. (NasdaqGS: BIIB) valued between $1,001 and $15,000. This transaction was reported on June 9, 2026, under the STOCK Act, which requires members of Congress to disclose their trades.

Biogen Inc. Stock Snapshot

Shares of Biogen Inc. are trading around $199.96. The company has a market cap of approximately $29.5 billion and a P/E ratio of 21.5, with a forward P/E of 12.0. Biogen's beta is quite low at 0.177, indicating lower volatility compared to the market. The stock's 52-week range is between $121.05 and $205.97, with a 50-day moving average of $188.47 and a 200-day moving average of $173.14.

Recent Earnings

Biogen reported revenue of about $9.94 billion, with a revenue growth of 1.9%. The company achieved a net margin of 13.8% and a return on equity of 7.7%. Biogen's next earnings report is expected on April 29, 2026.

Analysts Set New Price Targets

On June 8, 2026, Needham upgraded Biogen to a 'buy' rating, setting a price target of $255. RBC Capital maintained its 'buy' rating with a target of $227 on May 27, 2026. Piper Sandler reiterated its 'buy' rating with a $225 target on May 15, 2026. The consensus among 30 analysts is a 'buy' rating with a mean price target of $220.63.

Insider Buying and Selling at Biogen Inc.

Recent insider activity includes Menelas Pangalos buying 2,370 shares on June 9, 2026. Other insiders like Eric Rowinsky and Stephen Sherwin also bought shares on the same day.

About Biogen Inc.

Biogen Inc. is a healthcare company based in Cambridge, Massachusetts, specializing in therapies for neurological and neurodegenerative diseases. Led by CEO Christopher A. Viehbacher, the company employs around 7,500 people. Biogen's portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others.

Bottom Line

Maria Elvira's purchase of Biogen shares highlights the interest in the company's potential in the healthcare sector. With a solid market cap and a range of treatments, Biogen remains a significant player in its industry. Analyst recommendations and insider activities provide additional insights into the stock's outlook.